Ciltacabtagene Autoleucel

Definition

A preparation of autologous T-lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.

Also known as Autologous Anti-BCMA CAR-T Cells JNJ-68284528, Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528, Autologous Bi-epitope CAR T-cells JNJ-68284528, CARVYKTI, Cilta-cel, CILTACABTAGENE AUTOLEUCEL, JNJ 68284528, JNJ-68284528, JNJ68284528, LCAR B38M, LCAR-B38M, LCAR-B38M-transduced CAR-T Cells JNJ-68284528, LCARB38M — per NCIT

Also identified as

• ATC L01XL05 per RXNORM
• NCIT NCIT:C148498 per NCIT
• SCTID 1370976008 per RXNORM
• UNII 0L1F17908Q per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.